References
- Amornpisutt R, Proungvitaya S, Jearanaikoon P, et al (2015). DNA methylation level of OPCML and SFRP1: a potential diagnostic biomarker of cholangiocarcinoma. Tumour Biol, (in press).
- Buys SS, Partridge E, Black A, et al (2011). Effect of screening on ovarian cancer mortality: the prostate, lung, colorectal and ovarian (PLCO) cancer screening randomized controlled trial. JAMA, 305, 2295-303. https://doi.org/10.1001/jama.2011.766
- Clarke-Pearson DL (2009). Screening for ovarian cancer. New Engl J Med, 361, 170-7. https://doi.org/10.1056/NEJMcp0901926
- Chen H, Zhang C, Sheng Y, et al (2014). Frequent SOCS3 and 3OST2 promoter methylation and their epigenetic regulation in endometrial carcinoma. Am J Cancer Res, 5, 180-90.
- Guo S, Yan F, Xu J, et al (2015). Identification and validation of the methylation biomarkers of non-small cell lung cancer (NSCLC). Clin Epigenetics, 7, 3. https://doi.org/10.1186/s13148-014-0035-3
- Ji T, Zheng ZG, Wang FM, et al (2014). Differential microRNA expression by Solexa sequencing in the sera of ovarian cancer patients. Asian Pac J Cancer Prev, 15, 1739-43. https://doi.org/10.7314/APJCP.2014.15.4.1739
- Karami S, Andreotti G, Liao LM, et al (2015). LINE-1 methylation levels in pre-diagnostic leukocyte DNA and future renal cell carcinoma risk. Epigenetics, (in press).
- Liggett TE, Melnikov A, Yi Q, et al (2011). Distinctive DNA methylation patterns of cell-free plasma DNA in women with malignant ovarian tumors. Gynecol Oncol, 120, 113-20. https://doi.org/10.1016/j.ygyno.2010.09.019
- McIntosh MW, Liu Y, Drescher C, et al (2007). Validation and characterization of human kallikrein 11 as a serum marker for diagnosis of ovarian carcinoma. Clin Cancer Res, 13, 4422-8. https://doi.org/10.1158/1078-0432.CCR-06-2224
- Nelissen EC, van Montfoort AP, Dumoulin JC, et al (2011). Epigenetics and the placenta. Hum Reprod Update, 17, 397-417. https://doi.org/10.1093/humupd/dmq052
- Nordlund J, Bäcklin CL, Zachariadis V, et al (2015). DNA methylation-based subtype prediction for pediatric acute lymphoblastic leukemia. Clin Epigenetics, 7, 11. https://doi.org/10.1186/s13148-014-0039-z
- Pothuri B, Leitao MM, Levine DA, et al (2010). Genetic analysis of the early natural history of epithelial ovarian carcinoma. PLoS One, 5, 10358. https://doi.org/10.1371/journal.pone.0010358
- Shih IeM, Kurman RJ (2004). Ovarian tumorigenesis: a proposed model based on morphological and molecular genetic analysis. Am J Pathol, 164, 1511-8. https://doi.org/10.1016/S0002-9440(10)63708-X
- Siegel R, Deepa Naishadham MA, Ahmedin Jemal DVM (2013). Cancer statistics, 2013. CA Cancer J Clin, 63, 11-30. https://doi.org/10.3322/caac.21166
- Tost J (2010). DNA methylation: an introduction to the biology and the disease-associated changes of a promising biomarker. Mol Biotechnol, 44, 71-81. https://doi.org/10.1007/s12033-009-9216-2
- The Department of Health, Australian Government (2011). Cancer facts and figures. http://www.health.gov.au/internet/main/publishing.nsf/Content/cancer-facts
- Tiwawech D, Srisuttee R, Rattanatanyong P, et al (2014). Alu methylation in serum from patients with nasopharyngeal carcinoma. Asian Pac J Cancer Prev, 15, 9797-800. https://doi.org/10.7314/APJCP.2014.15.22.9797
- Wang B, Liu SZ, Zheng RS, et al (2014).Time trends of ovarian cancer incidence in China. Asian Pac J Cancer Prev, 15, 191-3. https://doi.org/10.7314/APJCP.2014.15.1.191
- Yu Shaorong, Liu Baorui, Lu Jianwei, et al (2013). Circulating DNA as potential biomarker for cancer individualized therapy. J Int Transl Med, 1, 144-51.
- Yamashita K, Waraya M, Kim MS, et al (2014). Detection of methylated CDO1 in plasma of colorectal cancer; a PCR study. PLoS One, 9, 113546. https://doi.org/10.1371/journal.pone.0113546
- Zhou F, Ma M, Tao G, et al (2014). Detection of circulating methylated opioid binding protein/cell adhesion moleculelike gene as a biomarker for ovarian carcinoma. Clin Lab, 60, 759-65.